Patients with symptomatic splenic MZL (as evidenced by splenomegaly or cytopenias) and without hepatitis C infection should undergo a trial of rituximab prior to the consideration of splenomegaly. Approximately 20% of splenic MZL is associated with autoimmune complications such as autoimmune hemolytic anemia, immune thrombocytopenia, cold agglutinin disease, and acquired von Willebrand disease.
Learn more about splenic MZL.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Christina Poh. Fast Five Quiz: Relapsed/Refractory Marginal Zone Lymphoma - Medscape - Nov 03, 2021.